Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …

Abstract Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions
through an anchored transmembrane molecule and a soluble circulating protein. Both …

In humans, the composition of gut commensal bacteria is closely correlated with obesity. The
bacteria modulate metabolites and influence host immunity. In this study, we attempted to …

The preproglucagon gene (Gcg) is expressed by specific enteroendocrine cells (L-cells) of
the intestinal mucosa, pancreatic islet α-cells, and a discrete set of neurons within the …

Long-term postprandial hyperglycemia is a primary risk factor for developing chronic
metabolic diseases such as obesity, type 2 diabetes, and cardiovascular disease. Chronic …

Summary Glucagon-like peptide-1 (GLP-1)-based therapies control glycemia in type 2
diabetic (T2D) patients. However, in some patients the treatment must be discontinued …

Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is a secreted peptide that acts as a
key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric …

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most frequent
neurodegenerative disorders. Despite their pathophysiological and clinical differences, they …

Glycolipid metabolism disorder are major threats to human health and life. Genetic,
environmental, psychological, cellular, and molecular factors contribute to their …

The regulation of energy and glucose balance contributes to whole-body metabolic
homeostasis, and such metabolic regulation is disrupted in obesity and diabetes. Metabolic …